Scientists map the genetic landscape of drug resistance in cancers

All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective second-line therapies.

Atai Life Sciences spotlights early depression data for psychedelic ahead of big readout

Less than two months after betting $50 million on Beckley Psytech’s psychedelic drugs, atai Life Sciences has shared initial Phase 2a results for one candidate

March 28, 2024

Experts, Senators Wrestle Over Thorny Drug Shortage Challenge

Experts from industry and academia and lawmakers reached consensus around the dangers and the drivers of drug shortages but clashed over approaches to solving the

December 7, 2023

Adding Atezolizumab Improves Survival in Advanced Cervical Cancer

First-line treatment with the anti-PD-L1 inhibitor atezolizumab (Tecentriq) combined with bevacizumab (Avastin) and platinum-based chemotherapy significantly improved survival in patients with metastatic or recurrent cervical

November 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.